100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant HT94252410733
Award Date
7/1/24
Completion Date
6/30/27
Dollars Obligated
$4.3M
Overview
Activity
2
Transactions
2
Subawards
Similar Awards
Federal Agency
Defense Health Agency
Awardee
Eliksa Therapeutics, Inc. (KXVVPMFRJC39)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Doylestown, PA 18901, USA
Update #1
Update #2
NOVEL OPHTHALMIC SOLUTION TO TREAT OCULAR MANIFESTATIONS OF EPIDERMOLYSIS BULLOSA
Posted 6/26/24
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
NOVEL OPHTHALMIC SOLUTION TO TREAT OCULAR MANIFESTATIONS OF EPIDERMOLYSIS BULLOSA THIS MODIFICATION: 1. EXTENDS THE PERIOD OF PERFORMANCE BY 12 MONTHS. 2. UPDATES DIVISION I ITEMS A.4, A.5.II, A.6, AND A7. ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED
$0
7/14/26
Not listed
NOVEL OPHTHALMIC SOLUTION TO TREAT OCULAR MANIFESTATIONS OF EPIDERMOLYSIS BULLOSA
$4.3m
6/26/24